September 4, 2024 published on nationalmssociety.org
When Rhonda Voskuhl, MD, began researching multiple sclerosis over a quarter of a century ago, she was an anomaly.Unlike many scientists at the time, Voskuhl wasn’t committed to “bench to bedside” research, which focuses on working with molecules in the lab and then seeing how the results apply to patients. As both a clinician and researcher, she thought it made more sense to observe a symptom in her patients, research its underlying mechanisms in the lab and then bring that research back to patients in a clinical trial.